{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:15:49Z","timestamp":1780593349987,"version":"3.54.1"},"reference-count":17,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>\n                    In this report, we examined the (1) activity of ceftazidime\u2013avibactam against clinical isolates\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                    , including those harboring\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>KPC<\/jats:sub>\n                    , (2) potential mechanisms leading to reduced susceptibility, and (3) activity of ceftazidime\u2013avibactam when combined with other agents. Of 802 carbapenem-resistant isolates of\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    gathered from New York City from 1999 to 2014, all were susceptible to ceftazidime\u2013avibactam. Minimum inhibitory concentrations (MICs) were higher in isolates with\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    , with the carbapenemase (KPC)-3 (compared to KPC-2), and those with a frameshift mutation in\n                    <jats:italic toggle=\"yes\">ompK<\/jats:italic>\n                    35. MICs did not appear to be affected by changes in\n                    <jats:italic toggle=\"yes\">ompK<\/jats:italic>\n                    36 or by expression of\n                    <jats:italic toggle=\"yes\">acrB<\/jats:italic>\n                    . Time-kill experiments demonstrated synergy between either polymyxin B or amikacin and ceftazidime\u2013avibactam in a minority of isolates. In conclusion, ceftazidime\u2013avibactam is active against\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    , including\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>KPC<\/jats:sub>\n                    isolates, in our region, but activity is affected by KPC subtype and by mutations in\n                    <jats:italic toggle=\"yes\">ompK<\/jats:italic>\n                    35. Synergy can occur when combined with polymyxin B or amikacin, but is unpredictable.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2016.0293","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T16:46:27Z","timestamp":1496853987000},"page":"35-39","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Activity of Ceftazidime\u2013Avibactam Against Clinical Isolates of\n                    <i>Klebsiella pneumoniae<\/i>\n                    , Including KPC-Carrying Isolates, Endemic to New York City"],"prefix":"10.1177","volume":"24","author":[{"given":"Nyla","family":"Manning","sequence":"first","affiliation":[{"name":"SUNY-Downstate Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Balabanian","sequence":"additional","affiliation":[{"name":"SUNY-Downstate Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rose","sequence":"additional","affiliation":[{"name":"SUNY-Downstate Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Landman","sequence":"additional","affiliation":[{"name":"SUNY-Downstate Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Quale","sequence":"additional","affiliation":[{"name":"SUNY-Downstate Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,1]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","article-title":"Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases","volume":"13","author":"Sylvia Munoz-Price L.","year":"2013","unstructured":"Sylvia Munoz-Price L., , Poirel L., , Bonomo R.A., , Schwaber M.J., , Daikos G.L., , Cormican M., , Cornaglia G., , Garau J., , Gniadkowski M., , Hayden M.K., , Kumarasamy K., , Livermore D.M., , Maya J.J., , Nordmann P., , Patel J.B., , Paterson D.L., , Pitout J., , Villegas M.V., , Wang H., , Woodford N., , and Quinn J.P.. 2013. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect. Dis., 13:785\u2013796.","journal-title":"Lancet Infect. Dis."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01222-13"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1128\/AAC.00826-13","article-title":"New \u03b2-lactamase inhibitors: a therapeutic renaissance in an MDR world","volume":"58","author":"Drawz S.M.","year":"2014","unstructured":"Drawz S.M., , Papp-Wallace K.M., , and Bonomo R.A.. 2014. New \u03b2-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob. Agents Chemother., 58:1835\u20131846.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02429-13"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1128\/AAC.04406-14","article-title":"Variants of \u03b2-lactamase KPC-2 that are resistant to inhibition by avibactam","volume":"59","author":"Papp-Wallace K.M.","year":"2015","unstructured":"Papp-Wallace K.M., , Winkler M., , Taracila M.A., , and Bonomo R.A.. 2015. Variants of \u03b2-lactamase KPC-2 that are resistant to inhibition by avibactam. Antimicrob. Agents Chemother., 59:3710\u20133717.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1128\/AAC.00678-15","article-title":"In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase","volume":"59","author":"Livermore D.M.","year":"2015","unstructured":"Livermore D.M., , Warner M., , Jamrozy D., , Mushtaq S., , Nichols W.W., , Mustafa N., , and Woodford N.. 2015. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob. Agents Chemother., 59:5324\u20135330.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate","volume":"59","author":"Humphries R.M.","year":"2015","unstructured":"Humphries R.M., , Yang S., , Hemarajata P., , Ward K.W., , Hindler J.A., , Miller S.A., , and Gregson A.. 2015. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob. Agents Chemother., 59:6605\u20136607.","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields R.K.","year":"2016","unstructured":"Shields R.K., , Potoski B.A., , Haidar G., , Hao B., , Doi Y., , Chen L., , Press E.G., , Kreiswirth B.N., , ClancyJ C.J., , and Nguyen M.H.. 2016. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin. Infect. Dis., 63,(12)::1615\u20131618.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1093\/jac\/dkw242","article-title":"The rise and fall of KPC-producing Klebsiella pneumoniae in New York City","volume":"71","author":"Abdallah M.","year":"2016","unstructured":"Abdallah M., , Olafisoye O., , Cortes C., , Urban C., , Landman D., , Ghitan M., , Collins B., , Bratu S., , and Quale J.. 2016. The rise and fall of KPC-producing Klebsiella pneumoniae in New York City. J. Antimicrob. Chemother., 71:2945\u20132948.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_11_2","unstructured":"Clinical and Laboratory Standards Institute. 2014. Performance Standards for Antimicrobial Susceptibility Testing. Approved standard M100-S24. Twenty-fourth Informational Supplement. Clinical Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1099\/jmm.0.012575-0","article-title":"Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae","volume":"58","author":"Landman D.","year":"2009","unstructured":"Landman D., , Bratu S., , and Quale J.. 2009. Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. J. Med. Microbiol., 58:1303\u20131308.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/jac\/dks063","article-title":"Transmission of carbapenem-resistant pathogens in New York city hospitals: progress and frustration","volume":"67","author":"Landman D.","year":"2012","unstructured":"Landman D., , Babu E., , Shah N., , Kelly P., , Olawole O., , Backer M., , Bratu S., , and Quale J.. 2012. Transmission of carbapenem-resistant pathogens in New York city hospitals: progress and frustration. J. Antimicrob. Chemother., 67:1427\u20131431.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1128\/AAC.37.9.1904","article-title":"Novel antibiotic regimens against Enterococcus faecium resistant to ampicillin, vancomycin, and gentamicin","author":"Landman D.","year":"1993","unstructured":"Landman D., , Mobarakai N., , and Quale J.M.. 1993. Novel antibiotic regimens against Enterococcus faecium resistant to ampicillin, vancomycin, and gentamicin. Antimicrob. Agents Chemother., 37; 1904\u20131908.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/AAC.49.7.3018-3020.2005","article-title":"Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection","volume":"49","author":"Bratu S.","year":"2005","unstructured":"Bratu S., , Mooty M., , Nichani S., , Landman D., , Gullans C., , Pettinato B., , Karumudi U., , Tolaney P., , and Quale J.. 2005. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother., 49:3018\u20133020.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1128\/AAC.00548-15","article-title":"Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum \u03b2-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae","author":"Shields R.K.","year":"2015","unstructured":"Shields R.K., , Clancy C.J., , Hao B., , Chen L., , Press E.G., , Iovine N.M., , Kreiswirth B.N., , and Nguyen M.H.. 2015. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum \u03b2-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob. Agents Chemother., 59; 5793\u20135797.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01585-15"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1128\/AAC.47.10.3332-3335.2003","article-title":"Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance","volume":"47","author":"Domenech-Sanchez A.","year":"2003","unstructured":"Domenech-Sanchez A., , Martinez-Martinez L., , Hernandez-Alles S., , del Carmen Conejo M., , Pascual A., , Tomas J.M., , Alberti S., , and Benedi V.J.. 2003. Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. Antimicrob. Agents Chemother., 47:3332\u20133335.","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2016.0293","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2016.0293","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2016.0293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:31:21Z","timestamp":1777667481000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2016.0293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1089\/mdr.2016.0293"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2016.0293","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}